MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2025 International Congress
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

Articles tagged "Dopamine"

  • MDS Virtual Congress 2021

    Connectomic Analysis of SNc and VTA Projections to the Striatum and Cortex

    N. Handfield-Jones, A. Owen, A. Khan, P. Macdonald (London, Canada)

    Objective: To investigate the dopaminergic neural tracts of healthy individuals using Diffusion MRI on Human Connectome Project Data. Background: Classically, the DA system has been…
  • MDS Virtual Congress 2021

    The effects of acute administration of VMAT2 inhibitors on extracellular levels of dopamine, norepinephrine, 5-HT and histamine in the striatum and medial prefrontal cortex

    E. Adler, L. Magid, O. Even-Chen, S. Schmidt, I. Cope, J. Alexander, J. Kehr, A. Orbach (Netanya, Israel)

    Objective: To evaluate the effects of reversible VMAT2 inhibitors (deutetrabenazine, tetrabenazine and valbenazine) on extracellular levels of monoamines and their acidic metabolites in rat striatum…
  • MDS Virtual Congress 2021

    Istradefylline/L-DOPA combination therapy for Parkinson’s disease and blood markers of glycolytic energy homeostasis

    NAO. Kanzato, KO. Nakachi, MA. Hayashi, F. Kinjyo, W. Mizuta, SA. Mochizuki (Haebaru-Cho, Okinawa, Japan)

    Objective: To clarify the potential to preserve glycolytic energy homeostasis (GEH) with the Istradefylline combined to L-DOPA (IST-LD), and to prevent LD-induced weight loss and…
  • MDS Virtual Congress 2021

    OPTIMIPARK Questionnaire:a tool to optimize treatment in Parkinson´s disease.

    J. Máñez-Miró, F. Vivancos-Matellano, L. Vela-Desojo, R. Martinez-Fernandez, F. Alonso-Frech, N. Lopez-Aristegui, E. Balaguer-Martínez, J. Martinez-Castrillo, L. Lopez-Manzanares, P. Martínez-Martín (Madrid, Spain)

    Objective: To validate the OPTIMIPARK questionnaire as a tool to help the clinician in the adjustment of dopaminergic treatment in Parkinson´s disease(PD). Background: At early…
  • MDS Virtual Congress 2021

    Influence of Dopamine Transporter Gene Polymorphism on Wearing Off

    CE. Mantese, V. Altmann, A. Schumacher-Schuh, M. Hutz, CRM. Rieder (Porto Alegre, Brazil)

    Objective: To study the influence of Dopamine transporter gene polymorphism on Wearing off (WO) through 19 items wearing off questionnaire (WOQ-19) Background: The dopamine transporter…
  • MDS Virtual Congress 2021

    Parkinson’s Disease Medication Safety in the Inpatient Cohort of a Tertiary Centre

    A. Redmond, G. Richard, M. Penugonda, D. Bradley (Dublin 8, Ireland)

    Objective: Our study aimed to determine the accuracy of initial prescribing on hospital admission and the subsequent timing of administration of Parkinson’s disease (PD) medications…
  • MDS Virtual Congress 2021

    The responsiveness of arm swing to dopaminergic medication in Parkinson’s disease depends on task complexity

    E. Warmerdam, R. Romijnders, C. Hansen, M. Elshehabi, M. Zimmermann, F. Metzger, A. von Thaler, D. Berg, G. Schmidt, W. Maetzler (Kiel, Germany)

    Objective: The aim of this study is to analyse the responsiveness of arm swing during walking to dopaminergic medication in patients with Parkinson’s disease. Background:…
  • MDS Virtual Congress 2021

    Effects of dopaminergic medication on reinforcement learning in Parkinson’s disease depend on depressive symptoms

    J. Tichelaar, C. Sayali, R. Helmich, R. Cools (Nijmegen, Netherlands)

    Objective: To investigate the effect of depression and dopaminergic medication on reinforcement learning (RL) in Parkinson’s disease. Background: Dopaminergic medication in PD is known to…
  • MDS Virtual Congress 2021

    DAT-IQ improves power to detect longitudinal change in DaT deficit in SURE-PD3

    Z. Fan, J. Seibyl, K. Marek, M. Schwarzschild, E. Macklin, R. Gunn (London, United Kingdom)

    Objective: DATIQ has been developed as a novel analytical approach to improve the sensitivity and statistical efficiency of dopamine transporter (DaT) SPECT quantification over previously…
  • MDS Virtual Congress 2021

    Is dopamine replacement therapy an addictive drug?

    V. Fleury, E. Pirondini, C. Provins, D. Benis, D. Vandeville, P. Krack (Geneva, Switzerland)

    Objective: To identify common clinical and imaging abnormalities in Parkinson's disease patients and heroin-dependent patients compared with healthy controls in order to better understand the pathophysiology…
  • « Previous Page
  • 1
  • …
  • 6
  • 7
  • 8
  • 9
  • 10
  • …
  • 26
  • Next Page »

Most Viewed Abstracts

  • This Month
  • All Time
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Life expectancy with and without Parkinson’s disease in the general population
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • “Magic carpet for freezing of gait ” Evaluating a combination of patterned and pictographic visual cues.
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Effect of marijuana on Essential Tremor: A case report
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2025 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley